Skip to content
AnalystLens

BridgeBio Pharma Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 22, 2024
Period End
December 31, 2023
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · May ’23May ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers.

Its 10-K for fiscal 2023 reports a net loss of $653.3 milliona, compared with $484.7 million in 2022 and $586.5 million in 2021, and an accumulated deficit of $2.6 billion. Revenue fell to $9.3 million from $77.6 million, mainly because 2022 included license revenue from the Navire-BMS License Agreement. Research and development expense rose to $455.7 million from $399.5 million.

The company reported cash, cash equivalents and restricted cash of $392.6 millionb, and it said these resources, together with its investment in equity securities, will fund operations for at least the next 12 months. The lead late-stage asset is acoramidis for ATTR-CM. The NDA was accepted by the FDA with a PDUFA date of November 29, 2024, and the MAA was accepted by the EMA.

Three other programs are in Phase 3: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9. Subsequent to year-end, the company entered financing arrangements: a Funding Agreement under which purchasers would pay $500.0 millionc upon first FDA approval of acoramidis in exchange for 5% of global net sales (adjustable to 10% in 2027), and a Financing Agreement for a senior secured term loan of up to $750.0 million, with $450.0 million funded on January 17, 2024 to repay the prior Loan Agreement. Liquidity and leverage are significant: total consolidated indebtedness was $1.7 billion as of December 31, 2023, including the 2027 and 2029 convertible notes and the term loan.

The Financing Agreement requires a minimum unrestricted cash balance of $70.0 milliond and restricts dividends and certain transactions. The company also disclosed a February 7, 2024 license of infigratinib in Japan to Kyowa Kirin for a $100.0 million upfront payment.

Key Highlights

  1. Net loss of $653.3 million in 2023, up from $484.7 million in 2022; accumulated deficit of $2.6 billion.
  2. Revenue of $9.3 million in 2023 versus $77.6 million in 2022, a decline attributed mainly to 2022 license revenue from the Navire-BMS License Agreement.
  3. Acoramidis NDA for ATTR-CM accepted by the FDA with a PDUFA date of November 29, 2024; MAA accepted by the EMA.
  4. Positive Phase 3 ATTRibute-CM results at Month 30 (Win Ratio of 1.8, p<0.0001), though the Month 12 6MWD primary endpoint of Part A was not met.
  5. Total consolidated indebtedness of $1.7 billion at December 31, 2023, with a $450.0 million term loan funded January 17, 2024 under the Financing Agreement.
  6. Funding Agreement provides up to $500.0 million upon first FDA approval of acoramidis in exchange for 5% of global net sales, adjustable to 10% in 2027.
  7. Cash, cash equivalents and restricted cash of $392.6 million; the company states these and its equity investments fund operations for at least 12 months.

Financial Statements

FY2023 against FY2022

Line itemFY2023FY2022Change
Revenue$9.30M$77.65M−88.0%
Cost of Revenue$2.45M$3.43M−28.8%
Gross Profit$6.86M$74.21M−90.8%
R&D Expenses$455.71M$399.46M+14.1%
SG&A Expenses$150.59M$143.19M+5.2%
Operating Expenses$616.67M$589.85M+4.5%
Operating Income-$607.37M-$512.20M−18.6%
Interest Expense$34.23M$34.14M+0.3%
Net Income-$643.20M-$481.18M−33.7%
EPS (Basic)$-3.95$-3.26−21.2%
EPS (Diluted)$-3.95$-3.26−21.2%
Shares Outstanding (Basic)162.79M147.47M+10.4%
Shares Outstanding (Diluted)162.79M147.47M+10.4%

Frequently Asked Questions

  1. How much cash does BridgeBio have and how long will it last?

    As of December 31, 2023, the company held cash and cash equivalents of $375.9 million, restricted cash of $16.7 million and investment in equity securities of $58.9 million. The company expects these to fund operations for at least the next 12 months, though its operating plan could change and it may need additional funds sooner.

  2. What is the status of acoramidis and when is the regulatory decision expected?

    The FDA accepted the NDA for acoramidis for ATTR-CM on February 5, 2024, with a PDUFA date of November 29, 2024. The EMA accepted the MAA. The company cannot predict when or whether approval will be granted.

  3. How significant is the company's debt, and what restrictions come with it?

    Total consolidated indebtedness was $1.7 billion at December 31, 2023. The Financing Agreement requires a minimum unrestricted cash balance of $70.0 million and restricts items such as dividends, asset dispositions, additional indebtedness and certain affiliate transactions. A breach could result in a default and acceleration of the obligations.

  4. What did the company give up in the royalty monetization arrangement?

    Under the Funding Agreement, the purchasers would pay $500.0 million (net of certain transaction expenses) after first FDA approval of acoramidis. In return, they receive 5% of global net sales of acoramidis, which may adjust to a maximum of 10% in 2027, until receipt of a $950.0 million cap or a buy-out payment. The seller parties also granted a security interest in specific acoramidis assets.

  5. Why did revenue decline in 2023?

    Revenue decreased by $68.3 million, to $9.3 million, primarily because 2022 included license revenue recognized upon transfer of the license under the Navire-BMS License Agreement. Research and development expense increased to $455.7 million in 2023 from $399.5 million in 2022.